TY - JOUR
T1 - Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry
AU - Chioncel, O.
AU - Lainscak, M.
AU - Seferovic, P.M.
AU - Anker, S.D.
AU - Crespo-Leiro, M.G.
AU - Harjola, V.-P.
AU - Parissis, J.
AU - Laroche, C.
AU - Piepoli, M.F.
AU - Fonseca, C.
AU - Mebazaa, A.
AU - Lund, L.
AU - Ambrosio, G.A.
AU - Coats, A.J.
AU - Ferrari, R.
AU - Ruschitzka, F.
AU - Maggioni, A.P.
AU - Filippatos, G.
N1 - Export Date: 24 January 2018
CODEN: EJHFF
Correspondence Address: Chioncel, O.; University of Medicine Carol DavilaRomania; email: [email protected]
References: Maggioni, A.P., Dahlstrom, U., Filippatos, G., Chioncel, O., Crespo-Leiro, M., Drozdz, J., Fruhwald, F., Tavazzi, L., EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) (2013) Eur J Heart Fail, 15, pp. 808-817; Tavazzi, L., Senni, M., Metra, M., Gorini, M., Cacciatore, G., Chinaglia, A., Di Lenarda, A., Maggioni, A.P., Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry (2013) Circ Heart Fail, 6, pp. 473-481; Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., Falk, V., van der Meer, P., Developed with the special contribution of the Heart Failure Association (HFA) of the ESC (2016) Eur J Heart Fail, 18, pp. 891-975; Butler, J., Fonarow, G.C., Zile, M.R., Lam, C.S., Roessig, L., Schelbert, E.B., Shah, S.J., Gheorghiade, M., Developing therapies for heart failure with preserved ejection fraction: current state and future directions (2014) JACC Heart Fail, 2, pp. 97-112; Vaduganathan, M., Michel, A., Hall, K., Mulligan, C., Nodari, S., Shah, S.J., Senni, M., Gheorghiade, M., Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review (2016) Eur J Heart Fail, 18, pp. 54-65; Lam, C.S., Solomon, S.D., The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%) (2014) Eur J Heart Fail, 16, pp. 1049-1055; Fonarow, G.C., Stough, W.G., Abraham, W.T., Albert, N.M., Gheorghiade, M., Greenberg, B.H., O'Connor, C.M., Young, J.B., Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry (2007) J Am Coll Cardiol, 50, pp. 768-777; Bhatia, R.S., Tu, J.V., Lee, D.S., Austin, P.C., Fang, J., Haouzi, A., Gong, Y., Liu, P.P., Outcome of heart failure with preserved ejection fraction in a population-based study (2006) N Engl J Med, 355, pp. 260-269; Maggioni, A.P., Anker, S.D., Dahlstrom, U., Filippatos, G., Ponikowski, P., Zannad, F., Amir, O., Tavazzi, L., Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry (2013) Eur J Heart Fail, 15, pp. 1173-1184; Crespo-Leiro, M.G., Anker, S.D., Maggioni, A.P., Coats, A.J., Filippatos, G., Ruschitzka, F., Ferrari, R., Mebazaa, A., European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions (2016) Eur J Heart Fail, 18, pp. 613-625; Bursi, F., Weston, S.A., Redfield, M.M., Jacobsen, S.J., Pakhomov, S., Nkomo, V.T., Meverden, R.A., Roger, V.L., Systolic and diastolic heart failure in the community (2006) JAMA, 296, pp. 2209-2216; Dunlay, S.M., Roger, V.L., Weston, S.A., Jiang, R., Redfield, M.M., Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction (2012) Circ Heart Fail, 5, pp. 720-726; Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction (2006) N Engl J Med, 355, pp. 251-259; Poppe, K., Squire, I.B., Whalley, G., Kober, L., McAlister, F.A., McMurray, J.J.V., Pocock, S., Doughty, R., Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report (2013) Eur J Heart Fail, 15, pp. 1220-1227; Solomon, S.D., Anavekar, N., Skali, H., McMurray, J.J., Swedberg, K., Yusuf, S., Granger, C.B., Pfeffer, M.A., Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients (2005) Circulation, 112, pp. 3738-3744; Lam, C.S., Roger, V.L., Rodeheffer, R.J., Bursi, F., Borlaug, B.A., Ommen, S.R., Kass, D.A., Redfield, M.M., Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota (2007) Circulation, 115, pp. 1982-1990; Borlaug, B.A., Redfield, M.M., Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum (2011) Circulation, 123, pp. 2006-2014; Kalogeropoulos, A.P., Fonarow, G.C., Georgiopoulou, V., Burkman, G., Siwamogsatham, S., Patel, A., Li, S., Butler, J., Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction (2016) JAMA Cardiol, 1, pp. 510-518; Mann, D.L., Burkhoff, D., Is myocardial recovery possible and how do you measure it? (2012) Curr Cardiol Rep, 14, pp. 293-298; Hwang, S.J., Melenovsky, V., Borlaug, B.A., Implications of coronary artery disease in heart failure with preserved ejection fraction (2014) J Am Coll Cardiol, 63, pp. 2817-2827; The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis (2012) Eur Heart J, 33, pp. 1750-1757; Triposkiadis, F., Giamouzis, G., Parissis, J., Starling, R.C., Boudoulas, H., Skoularigis, J., Butler, J., Filippatos, G., Reframing the association and significance of co-morbidities in heart failure (2016) Eur J Heart Fail, 18, pp. 744-758; van Deursen, V.M., Urso, R., Laroche, C., Damman, K., Dahlström, U., Tavazzi, L., Maggioni, A.P., Voors, A.A., Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey (2014) Eur J Heart Fail, 16, pp. 103-111; Swedberg, K., Komajda, M., Böhm, M., Borer, J.S., Ford, I., Dubost-Brama, A., Lerebours, G., Tavazzi, L., Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study (2010) Lancet, 376, pp. 875-885; Fox, K., Ford, I., Steg, P.G., Tardif, J.C., Tendera, M., Ferrari, R., Ivabradine in stable coronary artery disease without clinical heart failure (2014) N Engl J Med, 371, pp. 1091-1099; Ferrari, R., Fox, K., Heart rate reduction in coronary artery disease and heart failure (2016) Nat Rev Cardiol, 13, pp. 493-501; Zafrir, B., Salman, N., Crespo-Leiro, M.G., Anker, S.D., Coats, A.J., Ferrari, R., Filippatos, G., Amir, O., Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology (2016) Eur J Heart Fail, 18, pp. 859-868; Bursi, F., Barbieri, A., Grigioni, F., Reggianini, L., Zanasi, V., Leuzzi, C., Ricci, C., Modena, M.G., Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study (2010) Eur J Heart Fail, 12, pp. 382-388
PY - 2017/12
Y1 - 2017/12
N2 - Aims: The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors for mortality at 1 year in each group. Methods and results: The European Society of Cardiology Heart Failure Long-Term Registry is a prospective, observational study collecting epidemiological information and 1-year follow-up data in 9134 HF patients. Patients were classified according to baseline LVEF into HF with reduced EF [EF 50% (HFpEF)]. In comparison with HFpEF subjects, patients with HFrEF were younger (64 years vs. 69 years), more commonly male (78% vs. 52%), more likely to have an ischaemic aetiology (49% vs. 24%) and left bundle branch block (24% vs. 9%), but less likely to have hypertension (56% vs. 67%) or atrial fibrillation (18% vs. 32%). The HFmrEF group resembled the HFrEF group in some features, including age, gender and ischaemic aetiology, but had less left ventricular and atrial dilation. Mortality at 1 year differed significantly between HFrEF and HFpEF (8.8% vs. 6.3%); HFmrEF patients experienced intermediate rates (7.6%). Age, New York Heart Association (NYHA) class III/IV status and chronic kidney disease predicted mortality in all LVEF groups. Low systolic blood pressure and high heart rate were predictors for mortality in HFrEF and HFmrEF. A lower body mass index was independently associated with mortality in HFrEF and HFpEF patients. Atrial fibrillation predicted mortality in HFpEF patients. Conclusions: Heart failure patients stratified according to different categories of LVEF represent diverse phenotypes of demography, clinical presentation, aetiology and outcomes at 1 year. Differences in predictors for mortality might improve risk stratification and management goals. © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology
AB - Aims: The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors for mortality at 1 year in each group. Methods and results: The European Society of Cardiology Heart Failure Long-Term Registry is a prospective, observational study collecting epidemiological information and 1-year follow-up data in 9134 HF patients. Patients were classified according to baseline LVEF into HF with reduced EF [EF 50% (HFpEF)]. In comparison with HFpEF subjects, patients with HFrEF were younger (64 years vs. 69 years), more commonly male (78% vs. 52%), more likely to have an ischaemic aetiology (49% vs. 24%) and left bundle branch block (24% vs. 9%), but less likely to have hypertension (56% vs. 67%) or atrial fibrillation (18% vs. 32%). The HFmrEF group resembled the HFrEF group in some features, including age, gender and ischaemic aetiology, but had less left ventricular and atrial dilation. Mortality at 1 year differed significantly between HFrEF and HFpEF (8.8% vs. 6.3%); HFmrEF patients experienced intermediate rates (7.6%). Age, New York Heart Association (NYHA) class III/IV status and chronic kidney disease predicted mortality in all LVEF groups. Low systolic blood pressure and high heart rate were predictors for mortality in HFrEF and HFmrEF. A lower body mass index was independently associated with mortality in HFrEF and HFpEF patients. Atrial fibrillation predicted mortality in HFpEF patients. Conclusions: Heart failure patients stratified according to different categories of LVEF represent diverse phenotypes of demography, clinical presentation, aetiology and outcomes at 1 year. Differences in predictors for mortality might improve risk stratification and management goals. © 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology
KW - Ambulatory
KW - Chronic
KW - Heart failure
KW - Left ventricular ejection fraction
KW - Outcomes
KW - adult
KW - age
KW - aged
KW - all cause mortality
KW - Article
KW - atrial fibrillation
KW - body mass
KW - chronic kidney failure
KW - controlled study
KW - disease registry
KW - female
KW - heart atrium enlargement
KW - heart failure
KW - heart failure with preserved ejection fraction
KW - heart failure with reduced ejection fraction
KW - heart left bundle branch block
KW - heart left ventricle ejection fraction
KW - heart left ventricle hypertrophy
KW - heart rate
KW - hospitalization
KW - human
KW - hypertension
KW - ischemic heart disease
KW - major clinical study
KW - male
KW - New York Heart Association class
KW - priority journal
KW - systolic blood pressure
U2 - 10.1002/ejhf.813
DO - 10.1002/ejhf.813
M3 - Article
C2 - 28386917
SN - 1388-9842
VL - 19
SP - 1574
EP - 1585
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 12
ER -
